Nachrichten zur Illumina Inc. Aktie

Illumina earnings beat by $0.05, revenue topped estimates By Investing.com

Illumina earnings beat by $0.05, revenue topped estimates…

Aktie von Illumina heute am Aktienmarkt gefragt (116,9609 €)

Im Plus liegt zur Stunde die Illumina-Aktie . Zuletzt zahlten Investoren für das Wertpapier 125,34 US-Dollar. Ein Wertanstieg von 2,50…

Genomics Luminary and former Illumina Executive Bob Kain Joins Single Technologies as an Advisor

Stockholm, Sweden, 23 April 2024 – Renowned genomics pioneer, Bob Kain, has joined Single Technologies as an advisor to support…

Illumina: EU-Genehmigung des Verkaufsplans für Grail - Aktienanalyse

New York (www.aktiencheck.de) - Illumina-Aktienanalyse von Evercore ISI: Vijay Kumar, Analyst von Evercore ISI, nimmt in einer aktuellen Aktienanalyse die Aktie…

Kurs fällt um 3,75 Prozent: Illumina-Aktie unter Druck (115,0253 €)

An der US-amerikanischen Börse fällt gegenwärtig die Illumina-Aktie negativ auf. Das Papier verliert deutlich an Wert. Mit einem Kurssturz von…

Global Theranostics Market Size To Worth USD 3.3 Billion By 2033 | CAGR of 5.68%

The Global Theranostics Market Size was Valued at USD 1.9 Billion in 2023 and the Worldwide Theranostics Market Size is…

EU approves Illuminas plan to divest cancer test maker Grail By Reuters

EU approves Illuminas plan to divest cancer test maker Grail…

illumin Holdings Inc. announces date for First Quarter 2024 Financial and Operating Results

TORONTO, April 11, 2024 (GLOBE NEWSWIRE) -- illumin Holdings Inc. (TSX: ILLM) (“illumin” or “Company”), a journey advertising…

Illumina CFO steps down amid executive shakeup

…

Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed

Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by…

Illumina CFO Goswami to depart, Summit Therapeutics Dhingra named successor By Reuters

Illumina CFO Goswami to depart, Summit Therapeutics Dhingra named successor…

Illumina: Downgrade

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von OTR Global stufen die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol:…

EU court should back Illuminas appeal against EU review of Grail deal, court adviser says By Reuters

EU court should back Illuminas appeal against EU review of Grail deal, court adviser says…

Illumina shares fall as Ichan reportedly abandons second proxy contest By Investing.com

Illumina shares fall as Ichan reportedly abandons second proxy contest…

Exclusive-Icahn drops Illumina board challenge threat, sources say

Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illuminas board, sparing the U.S. gene…

Exclusive-Icahn drops Illumina board challenge threat, sources say By Reuters

Exclusive-Icahn drops Illumina board challenge threat, sources say…

Illuminas Turnaround Play: Betting On NovaSeq X Amidst Rising Competitive Tides

…

ILLUMINA ALERT: Bragar Eagel & Squire, P.C. is Investigating Illumina, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Kursgewinne für den Anteilsschein von Illumina (126,1800 €)

Am US-amerikanischen Aktienmarkt notiert die Illumina-Aktie zur Stunde fester. Zuletzt zahlten Investoren für die Aktie 136,87 US-Dollar. Der Anteilsschein von…

dpa-AFX ProFeed